{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:40:26Z","timestamp":1793252426213,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.ejphar.2011.06.058","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T00:59:33Z","timestamp":1311901173000},"page":"317-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Inhibition of NF-\u03baB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells"],"prefix":"10.1016","volume":"668","author":[{"given":"Andrea","family":"Mencarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Renga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D'Amore","family":"Claudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fiorucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.06.058_bb0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nri2316","article-title":"Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut","volume":"8","author":"Artis","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0015","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cell.2006.06.049","article-title":"Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network","volume":"126","author":"Bookout","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0020","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1128\/IAI.68.12.7010-7017.2000","article-title":"Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease","volume":"68","author":"Cario","year":"2000","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.110.170225","article-title":"Therapeutic role of Rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation","volume":"335","author":"Cheng","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2005.12.008","article-title":"The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease","volume":"130","author":"Dring","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ejphar.2011.06.058_bb0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1708-8305.2006.00084.x","article-title":"Rifaximin treatment of pathogen-negative travelers' diarrhea","volume":"14","author":"DuPont","year":"2007","journal-title":"J. Travel Med."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0040","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/gut.2003.030205","article-title":"Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis","volume":"53","author":"Franchimont","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0045","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1073\/pnas.0308680101","article-title":"Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family","volume":"101","author":"Garlanda","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0050","doi-asserted-by":"crossref","first-page":"17882","DOI":"10.1074\/jbc.M601302200","article-title":"Role of NF-kappaB in regulation of PXR-mediated gene expression, a mechanism for the suppression of cytochrome P-4503A4 by pro-inflammatory agents","volume":"281","author":"Gu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0732-8893(93)90004-Q","article-title":"Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative","volume":"16","author":"Hoover","year":"1993","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0060","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1084\/jem.20011788","article-title":"Toll-like receptor 4 resides in the golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells","volume":"195","author":"Hornef","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in vitro and in vivo antibacterial activity","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0075","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2009.11.013","article-title":"Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei","volume":"35","author":"Jiang","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ni1018","article-title":"Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPARgamma and RelA","volume":"5","author":"Kelly","year":"2004","journal-title":"Nat. Immun."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2004.04.019","article-title":"Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes","volume":"127","author":"Langmann","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.107.121913","article-title":"Rifaximin is a gut-specific human pregnane X receptor activator","volume":"322","author":"Ma","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0095","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bcp.2010.08.022","article-title":"Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells","volume":"80","author":"Mencarelli","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00054725-200011000-00007","article-title":"The role of chemokines and chemokine receptors in mucosal inflammation","volume":"6","author":"Papadakis","year":"2000","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0110","first-page":"G495","article-title":"Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense","volume":"277","author":"Podolsky","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1365-2036.2006.02879.x","article-title":"Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin","volume":"23","author":"Prantera","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. III","key":"10.1016\/j.ejphar.2011.06.058_bb0120","article-title":"Rifaximin-EIR (Extended Intestinal Release) 400mg tablets in the treatment of moderately active crohn's disease: results of the international multicentre, randomised, double-blind, placebo-controlled trial retic-03","volume":"59","author":"Prantera","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/ni1192","article-title":"Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells","volume":"6","author":"Rimoldi","year":"2005","journal-title":"Nat. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2011.06.058_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000089776","article-title":"Experimental and clinical pharmacology of Rifaximin, a gastrointestinal selective antibiotic","volume":"73","author":"Scarpignato","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0135","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1053\/gast.1997.v113.pm9322516","article-title":"Differential and regulated expression of C\u2013X\u2013C, C\u2013C, and C-chemokines by human colon epithelial cells","volume":"113","author":"Yang","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2011.06.058_bb0140","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1172\/JCI26283","article-title":"Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation","volume":"116","author":"Zhou","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2011.06.058_bb0145","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ibd.20480","article-title":"Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease","volume":"14","author":"Zimmerman","year":"2008","journal-title":"Inflamm. Bowel Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911007680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911007680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:02:45Z","timestamp":1785412965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911007680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0014299911007680"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.06.058","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of NF-\u03baB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.06.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}